Skip to content

Warenkorb

Der Warenkorb ist leer.

Gesamt (exkl. MwSt.) £0,00
Warenkorb überprüfen & bezahlen
Proteine und Peptide

Human Lipopolysaccharide Binding Protein (LBP), Active Protein

Produktgrößen
50 ug
£689,00
RPU58890-50UG
100 ug
£899,00
RPU58890-100UG
1 mg
£3807,00
RPU58890-1MG
Über dieses Produkt
SKU:
RPU58890
Zusätzliche Namen:
LPS-Binding Protein
Anwendung:
Detection/Quantitation, Tissue Culture
Buffer:
Freeze-dried powder|PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
CE/IVD:
RUO
Weitere Details:
Human Lipopolysaccharide Binding Protein (LBP), Active Protein is a purified Prokaryotic Protein.
Formulierung:
Freeze-dried powder
Immunogen:
Lipopolysaccharide Binding Protein (LBP)
Molekulargewicht:
52kDa
Physischer Zustand:
freeze-dried
Reinheit:
>95%
Versandbedingungen:
Blue Ice
Lagerbedingungen:
-20[o]C Avoid freeze/thaw cycles.
Hersteller:
Biomatik
Typ:
Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins
Catalog Protein.JPG
Figure . SDS-PAGE
Figure . Western Blot
Figure. The binding activity of LBP with CD14.Lipopolysaccharide Binding Protein (LBP) is a soluble acute-phase protein that binds to bacterial lipopolysaccharide (or LPS) to elicit immune responses by presenting the LPS to important cell surface pattern recognition receptors called CD14 and TLR4. The protein encoded by this gene is involved in the acute-phase immunologic response to gram-negative bacterial infections. This protein is part of a family of structurally and functionally related proteins, including BPI, plasma cholesteryl ester transfer protein (CETP), and phospholipid transfer protein (PLTP). Besides, Cluster Of Differentiation 14 (CD14) has been identified as an interactor of LBP, thus a binding ELISA assay was conducted to detect the interaction of recombinant human LBP and recombinant human CD14. Briefly, LBP were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to CD14-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-LBP pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50uL stop solution to the wells and read at 450nm immediately. The binding activity of LBP and CD14 was shown in Figure 1, and this effect was in a dose dependent manner.